U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06984718) titled 'A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC' on May 15.
Brief Summary: This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.
Study Start Date: June 25
Study Type: INTERVENTIONAL
Condition:
HCC
Hepatocellular Carcinoma
Intervention:
BIOLOGICAL: AK104+lenvatinib
Subjects will receive AK104+lenvatinib until disease progression
DRUG: lenvatinib...